Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Executive summary

Conclusions

1 evidence topic · 21 sources

Summary
  • Approved indication and basis: the FDA approved Lembaz (adrabetadex) injection with an action date of 11/17/2026 to reduce the risk of mortality in adult and pediatric patients who weigh 7 kg or greater with NPC whose neurological manifestations started at less than 6 years of age. Safety and effectiveness have not been established in patients who weigh less than 7 kg or whose neurological manifestations started at 6 years of age or older. Before this approval, two therapies were approved for NPC, and neither had been shown to reduce the risk of death. Effectiveness rests on an integrated survival analysis in which 36 treated participants from Trials 1, 2, 3, and the expanded access program were matched to 26 external control participants from Study 1, an observational, prospective, natural history study; the weighted number of control participants was 36. The manufacturer states that the FDA determined that this comparison “served as the adequate and well-controlled study supporting approval”.
  • Survival result: deaths occurred in 12 (33.3%) treated and 24 (66.9%) external control participants, with a hazard ratio for death of 0.45 (95% CI 0.21, 0.95), which the label and the FDA describe as a 55% reduction in the risk of death. The FDA reported a median survival time of 8.5 years in the treated group and 4.9 years in the control group. A company analysis that matched 72 treated participants with 119 external controls from 4 major disease databases or publications reported a hazard ratio of 0.289 (95% CI 0.141, 0.593), and hazard ratios in comparisons to each individual external control cohort of 0.113 (95% CI 0.042, 0.301), 0.449 (95% CI 0.214, 0.946), and 0.381 (95% CI 0.128, 1.137; P = 0.1426).
  • Randomized trial result: in the 52-week, randomized, double-blind, sham-controlled period of Trial 1 (Parts A and B; 56 treatment-naïve participants), the mean change from baseline in the NPC-SS composite score at Week 52 was 0.0 (SD 2.45) with adrabetadex (n = 38) and -0.1 (SD 1.55) with sham (n = 18). The prior sponsor reported that the trial “did not show a statistically significant separation from placebo”, and protocol amendment 15 states that the analysis “shows no benefit of adrabetadex on the pre-specified co-primary endpoints”. In the VTS-270-001 protocol, Mallinckrodt concluded that “the benefit/risk balance is negative”. A company analysis of 79 treated participants compared post-treatment with pre-treatment rates of disease progression and reported 0.76 units per year after treatment against 1.34 units/year before treatment on the R4DNPCCSS (P=0.0055).
  • Safety: the label carries a boxed warning for hearing impairment, including permanent hearing loss, and calls for a comprehensive audiology evaluation before treatment. With upward titration guided by audiometry in Trial 3 and an expanded access program, 37% (22/59) of participants experienced hearing impairment. In Trial 1 Parts A and B, hearing impairment occurred in 23 (71.9%) participants receiving up to 900 mg and 8 (44.4%) receiving sham, and ataxia in 22 (68.8%) and 5 (27.8%). LEMBAZ is administered intrathecally every 2 weeks over 1 to 2 minutes by, or under the supervision of, a healthcare provider experienced in performing lumbar punctures.
  • Eligible population: Beren Therapeutics states that approximately half of those living with NPC in the U.S., 475 children, have infantile-onset NPC, and that approximately two-thirds of people with NPC in the U.S. remain undiagnosed. One analysis estimated 943 prevalent cases of NPC, or 2.9 cases of NPC per million people in the United States.
  • Price and economic evidence: trade press reporting on the approval states that “List pricing for the new product has not yet been announced”. No budget impact model or cost-effectiveness analysis of adrabetadex has been published, and the NICE appraisal of VTS-270 was suspended after information the company provided in July 2023 and then discontinued. For comparison, the ICER Launch Price and Access Report (2026) gives annual list prices of $967,432.50 for Miplyffa (arimoclomol) and $701,321.42 for Aqneursa (levacetylleucine).
  • Main uncertainties: the approval rests on a comparison with external controls, and a company presentation of the analysis's methods states that externally controlled analyses are susceptible to bias from differences in baseline prognosis, treatment initiation at different ages, calendar time and standards of care, and post-baseline therapies. The data request that proposed the external control analysis stated that “All planned statistical analyses are exploratory”. The hazard ratio differed between the label analysis and the company analysis and across the individual external control cohorts. The randomized period of Trial 1 did not show a statistically significant separation from placebo. Part C of Trial 1 and VTS-270-001 were terminated by the sponsor; efficacy endpoints for Part C were not reported after 20 January 2021, and under the amended VTS-270-001 protocol efficacy assessments were not collected or analyzed.